Catalyst Dossier · compiled by CeliA 🧫
Aprea Therapeutics, Inc. (APRE)
Pharmaceutical Preparations · market cap $9M · as of 2026-07-22
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
5
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Aprea Therapeutics (APRE) is a micro-cap pharmaceutical company with a market cap of approximately $9M and 8 employees, focused on oncology. Its lead asset, APR-246 in combination with azacitidine, is in Phase 3 development for myelodysplastic syndromes (MDS), with additional pipeline programs in AML, ovarian cancer, and solid tumors. No upcoming catalysts are currently scheduled, and key financial details including cash position and runway are undisclosed.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| APR-246 + azacitidine | Phase 3 | MDS |
| Pegylated Liposomal Doxorubicin Hydrochloride (PLD) | Phase 2 | High-grade Serous Ovarian Cancer |
| APR-246 | Phase 2 | Acute Myeloid Leukemia or Myelodysplastic Syndromes |
| ATRN-119 | Phase 2 | Advanced Solid Tumor |
| Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD) | Phase 2 | Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53 |
Price & technical context
3-month
-39.0%
6-month
-51.0%
12-month
-73.7%
52-wk range
$0.91–$4.30
vs 50-day MA
-27.8%
vs 200-day MA
-43.3%
Realized vol
72.9%
Max drawdown
-89.2%
Daily closes through 2025-12-11. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for APRE (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.